Goodbye IMI, Hello IHI: New EU Partnership Prepares To Invite Research Proposals
Broadened membership includes medtech and digital health
The new iteration of the EU’s successful public-private R&D partnership promises to increase the support for medtech and digital platforms as well pharmaceutical research, with the aim of producing innovative cross-sectoral projects in areas such as drug/device combinations and AI-based diagnostics.
You may also be interested in...
The EU’s new public-private partnership, the Innovative Health Initiative, plans to involve a wide range of stakeholders in research projects aimed at developing new drugs, diagnostics and medical devices. At its launch event this week, two of its top officials described how the venture would work, who could get involved, and the challenges in doing so.
Cross-industry collaboration is the new focus of EU health care technology research funding activity. Under Horizon Europe, the Innovative Health Initiative will encourage convergence in health technology, and prioritize digital technologies and data analytics. No longer can EU-funded projects be pharma-only or medtech-only, said MedTech Europe’s Patrick Boisseau.
Industry representatives told a House of Lords committee about continuing Brexit-related problems such as the extra work involved in checking compliance with the EU Falsified Medicines Directive and the drawbacks of a proposed “dual regulatory regime.”